Supplementary Table 1. Adverse events (N=31)

Characteristic	Value
AE	12 (38.7)
Drug-related AE	3 (9.7)
Grade III or higher AE	2 (6.5)
Serious AE	2 (6.5)
Particular concerns AE	2 (6.5)
AE resulting in the cessation of treatment	1 (3.2)
No. of AE	1.10±2.36
AE level	
0	19 (61.3)
1	2 (6.5)
2	7 (22.6)
3	2 (6.5)
Unknown	1 (3.2)

Values are presented as number (%) or mean±standard deviation.
AE, adverse events.

Supplementary Table 2. Drug exposure

Characteristic	Dose-adjustment period (n=29)	Dose-stabilization period (n=29)
Drug exposure time (day)	79.10±4.51	351.45±25.77
Prescribed number of treatment courses	12.00±0.00	50.97±2.10
Actual number of doses administered	11.86±0.44	50.31±4.05
Compliance (%)	98.85±0.04	97.69±0.06
Total dose administered (mg)	19.51±4.73	171.68±70.89
Average dose per dose (mg/wk)	1.64±0.39	3.40±1.34

Values are presented as mean±standard deviation.

Supplementary Table 3. IGF-1 SDS level

Characteristic	Baseline (n=31)	4 Weeks (n=26)	8 Weeks (n=25)	12 Weeks (n=28)	38 Weeks (n=28)	64 Weeks (n=28)	*P*-value†	
							Baseline vs. 38 weeks	Baseline vs. 64 weeks
IGF-1 SDS	-3.07±1.20	-2.09±1.09	-1.59±1.27	-1.53±1.25	-1.24±1.11	-1.38±1.62	<0.001	<0.001
IGF-1 SDS change from baseline	NA	1.14±0.80	1.44±0.97	1.58±1.00	1.86±1.24	1.80±1.65		

Values are presented as mean±standard deviation.
IGF-1, insulin-like growth factor-1; SDS, standard deviation score; NA, not applicable.
†Paired *t*-test.